Tuomas Knowles
From Wikipedia, the free encyclopedia
Tuomas Knowles | |
|---|---|
| Alma mater | ETH Zurich, University of Cambridge, University of Geneva |
| Known for | Protein biophysics |
| Awards | Corday–Morgan Prize from the Royal Society of Chemistry, Raymond and Beverly Sackler International Prize in Biophysics, Harrison-Meldola Memorial Prize from the Royal Society of Chemistry, Rita and John Cornforth Award, Royal Society of Chemistry, 2019 |
| Scientific career | |
| Fields | Biophysics, Chemistry, Physical Chemistry[1] |
| Institutions | University of Cambridge |
| Doctoral advisor | Sir Mark Welland |
| Other academic advisors | Sir Chris Dobson |
Tuomas Knowles is a British scientist and Professor of Physical Chemistry and Biophysics at the Department of Chemistry[2] and at the Cavendish Laboratory at the University of Cambridge.[3] He is the co-director of the Cambridge Centre for Misfolding Diseases[4] and a Fellow of St John's College, Cambridge.[5][circular reference] Prof. Knowles is a co-founder of four biotechnology companies: Fluidic Analytics, Wren Therapeutics, Xampla and Transition Bio. He was also the Cambridge Enterprise Academic Entrepreneur of the year in 2019.[6]
Tuomas Knowles studied Biology at the University of Geneva and Physics at the Swiss Federal Institute of Technology in Zurich and at the University of Cambridge. He holds a Ph.D. in Physics from the University of Cambridge and a master's degree in Physics from the Swiss Federal Institute of Technology Zurich. He was a visiting scholar at Harvard University[7] and Weston Visiting Professor at the Weizmann Institute of Science in Israel.
